CJC-1295

Mechanism of Action

Modified growth hormone-releasing hormone (GHRH) analogue. With DAC (drug affinity complex), binds albumin to extend half-life, producing sustained pulsatile GH and IGF-1 elevation.

Typical Protocol

Educational reference only — not medical advice.

Pharmacokinetics & Dosing Rationale

CJC-1295 is administered subcutaneous injection with an approximate systemic half-life of ~8 days (with DAC); ~30 min (without DAC). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Weekly) is designed to match receptor kinetics rather than plasma exposure. Modified growth hormone-releasing hormone (GHRH) analogue. With DAC (drug affinity complex), binds albumin to extend half-life, producing sustained pulsatile GH and IGF-1 elevation.

How to Administer

1. Route: Subcutaneous injection. Typical starting dose 1–2 mg (with DAC), Weekly.
2. Timing: Evening, fasted — keep it the same each dosing day to make effects legible.
3. Cycle length: 8–12 week cycles. Reassess with bloods and symptom logs before repeating.
4. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Reconstitution & Injection Technique

1. Reconstitute lyophilised powder with bacteriostatic water (0.9% benzyl alcohol) — sterile water is acceptable but shortens shelf life to ~72 hours.
2. Typical dilution: add 2 mL of bacteriostatic water to a 5 mg vial → 2.5 mg/mL; a 10-unit insulin syringe mark = 0.25 mg.
3. Inject the diluent slowly against the vial wall — never onto the powder — and gently swirl. Do not shake; peptides denature under shear.
4. Once reconstituted, store upright in the refrigerator (2–8 °C) and use within 30 days.
5. Draw the dose with an insulin syringe (29–31G, 8 mm), swab the site with alcohol, pinch subcutaneous tissue on the abdomen or thigh, inject at 90°.

Sterile technique is not optional. Use a fresh needle for every injection.

Cycling & Stacking Strategy

• Standard protocol: 1–2 mg (with DAC), Weekly, for 8–12 week cycles.
• Ramp up: start at the lower end of the dose range for the first 7–10 days to gauge tolerance and side effects before titrating.
• Break periods let receptor sensitivity and endogenous feedback loops normalise — running back-to-back cycles without a wash-out erodes the effect.
• Common stack: Ipamorelin, Resistance training, Adequate protein. Introduce one compound at a time so you can attribute effect and side effect.

Who This Is For

What to Monitor

Reported Benefits

• Sustained elevation of GH and IGF-1
• Improved sleep depth (slow-wave sleep)
• Reported body composition improvements

Safety Profile

Common Mistakes

• Chasing a bigger dose instead of consistency — CJC-1295 outcomes track cumulative exposure, not peak concentration.
• Skipping baseline bloods, so there is no way to know whether the cycle actually moved a biomarker.
• Stacking three or four novel compounds at once — you lose the ability to attribute any effect or side effect.
• Ignoring the training, sleep and nutrition fundamentals that are prerequisites for every peptide protocol.
• Reusing insulin needles or failing to rotate injection sites — a preventable cause of local reactions and lipohypertrophy.
• Injecting immediately after a meal — insulin blunts the GH pulse. Fasted, pre-bed dosing is the point.

Evidence Grade — B

Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Below are the primary references used to grade CJC-1295. Follow the links for full-text where available and cross-check against the current literature.

Frequently Asked Questions

References

1. [1]Sustained GH and IGF-1 responses to CJC-1295 in healthy adults — Journal of Clinical Endocrinology & Metabolism, 2006

Further reading: Research library → · Protocols →